| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
1 company
Alicia Secor is Chief Commercial Officer at LRMR. Alicia Secor's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Alicia Secor has 5 Form 4 filings on record from February 2015 to June 2026, across 2 companies: Director at Zevra Therapeutics (ZVRA), 2025–2026; Chief Commercial Officer at Larimar Therapeutics (LRMR), 2015–2016.
The 8 reported transactions were 5 option or other derivative awards, 2 open-market sales and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $1.1M.
The only open-market sale was 26,256 shares of LRMR at an average $41.05 on September 17, 2015, about $1.1M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2015 | LRMR Larimar Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 26,256 | $41.05 | $1,077,808.80 | - |